Comparison of Renal Response Parameters for Juvenile Membranous Plus Proliferative Lupus Nephritis Versus Isolated Proliferative Lupus Nephritis: a Cross-sectional Analysis of the CARRA Registry

Overview

Journal Lupus

Publisher Sage Publications

Specialty Rheumatology

Date 2014 Apr 15

PMID 24729278

Citations 10

Authors

A Boneparth

N T Ilowite

Affiliations

Soon will be listed here.

Abstract

Lupus nephritis (LN) affects many patients with juvenile systemic lupus erythematosus (SLE) and is a significant cause of disease morbidity. Membranous plus proliferative LN (M + PLN) may represent a more difficult to treat subtype of juvenile LN, compared to isolated proliferative LN (PLN). In this retrospective observational study, we utilized data from the Childhood Arthritis and Rheumatism Research Alliance (CARRA) registry to compare response rates for pediatric M + PLN versus PLN. Response was assessed at the most recent CARRA registry visit gathered ≥6 months after diagnostic kidney biopsy. Estimated glomerular filtration rate (GFR) less than 90 ml/min/1.73 m(2), indicating renal insufficiency, was found in 16.1% of patients with M + PLN and 6.1% of patients with PLN (P = 0.071). We found no significant difference in achievement of response in either hematuria or proteinuria between PLN and M + PLN groups or between subgroups determined by presence of class III vs. class IV proliferative disease. Exposure rates to mycophenolate, cyclophosphamide, and rituximab were similar between groups. Future studies will be necessary to correlate pediatric LN renal histology data with treatment response as well as other disease outcome measures.

Citing Articles

Childhood-Onset Lupus Nephritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: Short-Term Kidney Status and Variation in Care.

Smitherman E, Chahine R, Beukelman T, Lewandowski L, Rahman A, Wenderfer S Arthritis Care Res (Hoboken). 2023; 75(7):1553-1562.

PMID: 36775844 PMC: 10500561. DOI: 10.1002/acr.25002.

Advances in proteomic profiling of pediatric kidney diseases.

Cummins T, Korte E, Bhayana S, Merchant M, Barati M, Smoyer W Pediatr Nephrol. 2022; 37(10):2255-2265.

PMID: 35220505 PMC: 9398920. DOI: 10.1007/s00467-022-05497-2.

Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE.

Gilbert M, Goilav B, Hsu J, Nietert P, Meidan E, Chua A Pediatr Rheumatol Online J. 2021; 19(1):137.

PMID: 34461932 PMC: 8404338. DOI: 10.1186/s12969-021-00627-w.

Principles of pediatric lupus nephritis in a prospective contemporary multi-center cohort.

Vazzana K, Daga A, Goilav B, Ogbu E, Okamura D, Park C Lupus. 2021; 30(10):1660-1670.

PMID: 34219529 PMC: 10461610. DOI: 10.1177/09612033211028658.

The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months.

Beukelman T, Kimura Y, Ilowite N, Mieszkalski K, Natter M, Burrell G Pediatr Rheumatol Online J. 2017; 15(1):30.

PMID: 28416023 PMC: 5392971. DOI: 10.1186/s12969-017-0160-6.

References

. Lupus nephritis: prognostic factors and probability of maintaining life-supporting renal function 10 years after the diagnosis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL). Am J Kidney Dis. 1992; 19(5):473-9. DOI: 10.1016/s0272-6386(12)80957-7. View

Lau K, Ault B, Jones D, Butani L . Induction therapy for pediatric focal proliferative lupus nephritis: cyclophosphamide versus mycophenolate mofetil. J Pediatr Health Care. 2008; 22(5):282-8. DOI: 10.1016/j.pedhc.2007.07.006. View

Bao H, Liu Z, Xie H, Hu W, Zhang H, Li L . Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008; 19(10):2001-10. PMC: 2551567. DOI: 10.1681/ASN.2007121272. View

Ginzler E, Dooley M, Aranow C, Kim M, Buyon J, Merrill J . Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005; 353(21):2219-28. DOI: 10.1056/NEJMoa043731. View

Weening J, DAgati V, Schwartz M, Seshan S, Alpers C, Appel G . The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004; 15(2):241-50. DOI: 10.1097/01.asn.0000108969.21691.5d. View

Jacobsen S, Starklint H, Petersen J, Ullman S, Junker P, Voss A . Prognostic value of renal biopsy and clinical variables in patients with lupus nephritis and normal serum creatinine. Scand J Rheumatol. 1999; 28(5):288-99. DOI: 10.1080/03009749950155464. View

Hochberg M . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40(9):1725. DOI: 10.1002/art.1780400928. View

Emre S, Bilge I, Sirin A, Kilicaslan I, Nayir A, Oktem F . Lupus nephritis in children: prognostic significance of clinicopathological findings. Nephron. 2001; 87(2):118-26. DOI: 10.1159/000045899. View

Wofsy D, Hillson J, Diamond B . Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials. Arthritis Rheum. 2013; 65(6):1586-91. PMC: 4398144. DOI: 10.1002/art.37940. View

10.

Schwartz G, Munoz A, Schneider M, Mak R, Kaskel F, Warady B . New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009; 20(3):629-37. PMC: 2653687. DOI: 10.1681/ASN.2008030287. View

11.

Gibson K, Gipson D, Massengill S, Dooley M, Primack W, Ferris M . Predictors of relapse and end stage kidney disease in proliferative lupus nephritis: focus on children, adolescents, and young adults. Clin J Am Soc Nephrol. 2009; 4(12):1962-7. PMC: 2798882. DOI: 10.2215/CJN.00490109. View

12.

Hiraki L, Benseler S, Tyrrell P, Hebert D, Harvey E, Silverman E . Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr. 2008; 152(4):550-6. DOI: 10.1016/j.jpeds.2007.09.019. View

13.

Donadio Jr J, HART G, Bergstralh E, HOLLEY K . Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus. 1995; 4(2):109-15. DOI: 10.1177/096120339500400206. View

14.

Marks S, Sebire N, Pilkington C, Tullus K . Clinicopathological correlations of paediatric lupus nephritis. Pediatr Nephrol. 2006; 22(1):77-83. DOI: 10.1007/s00467-006-0296-y. View

15.

Schwartz G, Work D . Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol. 2009; 4(11):1832-43. DOI: 10.2215/CJN.01640309. View

16.

Najafi C, Korbet S, Lewis E, Schwartz M, Reichlin M, Evans J . Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int. 2001; 59(6):2156-63. DOI: 10.1046/j.1523-1755.2001.00730.x. View

17.

Moroni G, Quaglini S, Gallelli B, Banfi G, Messa P, Ponticelli C . The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Transplant. 2007; 22(9):2531-9. DOI: 10.1093/ndt/gfm245. View

18.

Wofsy D, Hillson J, Diamond B . Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum. 2012; 64(11):3660-5. DOI: 10.1002/art.34624. View

19.

Lee B, Cho H, Kim E, Kang H, Ha I, Cheong H . Clinical outcomes of childhood lupus nephritis: a single center's experience. Pediatr Nephrol. 2006; 22(2):222-31. DOI: 10.1007/s00467-006-0286-0. View

20.

MacGowan J, Ellis S, Griffiths M, Isenberg D . Retrospective analysis of outcome in a cohort of patients with lupus nephritis treated between 1977 and 1999. Rheumatology (Oxford). 2002; 41(9):981-7. DOI: 10.1093/rheumatology/41.9.981. View